Extra costs tied to administering expensive specialty drugs

July 2008
Employee Benefit News;Jul2008, Vol. 22 Issue 9, p44
The article deals with the need for U.S. employers to become more knowledgeable about managing the costs of administering specialty drugs. According to Goldman Sachs, specialty drugs are expected to increase 14% annually through 2011 because of new drugs entering the market. Dell Mather of Ancillary Care Management notes the proposed introduction of a separate benefit for speciality drugs to address the increasing costs and burgeoning number of new biologic products.


Related Articles

  • Opportunities for the Cost Reduction of Medical Care. Malach, Monte; Baumol, W. J. // Journal of Community Health;Aug2009, Vol. 34 Issue 4, p255 

    The explosion of medical knowledge has deluged the medical community with a plethora of new medicines, new tests, and new procedures. This creates a serious need to carefully evaluate the definable benefits from these new developments, which promise to increase the quality of medical care beyond...

  • Multidrug regimens cost effective in prevention of CVD.  // PharmacoEconomics & Outcomes News;8/26/2006, Issue 510, p5 

    The article presents the results of a cost effectiveness analysis of multidrug regimens for the primary and secondary prevention of cardiovascular disease (CVD) in low- and middle-income countries. The analysis revealed that secondary prevention regimen decreased the lifetime risk of death from...

  • Do's and dont's of prescription drugs.  // Current Health 1;Oct98, Vol. 22 Issue 2, p18 

    Deals with the advantage and the disadvantages of taking prescription drugs. Types of information that can be seen on a medicine bottle label; Tips when taking prescription drugs; Side effects and allergies of drugs.

  • prescriptions for safety. Smetzer, Judy // AHA News;07/24/2000, Vol. 36 Issue 29, p5 

    Focuses on the management of sample drugs. Problems encountered when dispensing sample drugs; Recommendations on safe practice for sample drugs.

  • Employers must examine extra costs tied to administering specialty drugs. Bridgeford, Lydell C. // Employee Benefit Adviser;Aug2008, Vol. 6 Issue 8, p10 

    This article discusses the need for employers to be more aware of the extra costs linked to administering specialty drugs. According to Dana Felthouse, president of the Pharmacy Benefit Management Institute, the number of distribution channels for specialty drugs is increasing. As stated,...

  • DIRECT COMMUNICATIONS HELP LIMIT WORKERS COMP DRUG COSTS. KERTESZ, LOUISE // Business Insurance;12/2/2013, Vol. 47 Issue 24, p0006 

    The article reports on the deployment by employers and health care administrators of data and communication to prevent workers compensation prescription drug costs from increasing in 2013. It mentions the plans of the U.S. Food and Drug Administration (FDA) to increase access restriction to...

  • Health Economic Analysis. Schultz, Monica; Lyle, Chris // Applied Clinical Trials;May2009, Vol. 18 Issue 5, p40 

    The article discusses the cost effectiveness criteria in the U.S. It highlights the cost effectiveness criteria that created controversy which remained in circulation for 10 years. It notes the argument on incorporating costs and outcome considerations for treatment decision of a patient that...

  • 21 CFR Part 11 and Risk Assessment: Adapting Fundamental Methodologies to a Current Rule. Lander, Victoria // Pharmaceutical Technology Europe;May2004, Vol. 16 Issue 5, p47 

    In September 2003, FDA released the 21 CFR Part 11 scope and applicability final guidance document, addressing industry concerns regarding the complexity and cost of Part 11 compliance. As the guidance states FDA's intentions to take a more discretionary risk-based approach to enforcing...

  • PERSONALIZED MEDICINE: Keeping Up with Change. Tufel, Gary // Clinical Lab Products;Jun2013, Vol. 43 Issue 6, p8 

    The article discusses developments in personalized medicine diagnostics as of June 2013. The U.S. Food and Drug Administration (FDA) has announced its approval of Tarceva for its use in first-line treatment of non-small cell lung cancer. It observes that personalized medicine continue to present...


Read the Article


Sign out of this library

Other Topics